Two Lower Olanzapine Doses to Prevent Nausea in Myeloma Patients
Compares two lower olanzapine doses to prevent nausea in people with multiple myeloma receiving melphalan.
Key facts
- Who runs it
- Augusta University
- Where
- Augusta, United StatesSee the site
- Trial code
- Registry title
- Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 172 people, planned
- Started
- 17 Sept 2024
- Expected to end
- Oct 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Olanzapine
- Record updated
- 22 November 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults having an autologous stem cell transplant after high-dose melphalan chemotherapy. It compares two low doses of olanzapine to prevent nausea and vomiting.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Multiple myeloma; receiving high-dose melphalan 140-200 mg/m2 before an autologous stem cell transplant
- Earlier treatment
- No other antipsychotic medicine within 30 days before joining, or planned during the trial
Main reasons for not taking part
- Allergy to olanzapine
- Nausea or vomiting within 24 hours before joining
- Other antipsychotic medicines such as risperidone, quetiapine, clozapine, phenothiazine or butyrophenone
- Chronic alcoholism
- Pregnant
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Receipt of high-dose melphalan 140-200 mg/m2
- Autologous stem cell transplantation recipient
Who cannot take part
- Documented nausea or vomiting within 24 hours prior to enrollment
- Treatment with other antipsychotic agents such as risperidone, quetiapine, clozapine, phenothiazine, or butyrophenone within 30 days prior to enrollment or planned during protocol therapy
- Allergy to olanzapine
- Chronic alcoholism
- Pregnant
- Decline or unable to provide informed consent
Where in United States
- Wellstar MCGAugusta, United StatesContact: Amber Clemmons, PharmDTaking people
About the trial
What the trial wants to find out
Patients who receive a chemotherapy called melphalan are at high risk of having nausea and vomiting. A medication called olanzapine has been shown to decrease nausea and vomiting after chemotherapy. A previous research study found the 10 mg dose of olanzapine (combined with 3 standard medications used routinely to prevent nausea/vomiting) to be effective for patients who received melphalan chemotherapy, but several other studies have shown many patients have a side effect of sleepiness (e.g., sedation) with that dose of the medication. Our study will compare two lower doses of olanzapine (5 mg and 2.5 mg) in combination with the 3 standard medications used to prevent nausea/vomiting in the patients who receive melphalan chemotherapy to determine which dose is effective in preventing nausea and vomiting with the lowest amount of sleepiness side effect.
The 2 groups in the trial
- Olanzapine 2.5 mgTreatment being tested
Olanzapine 2.5 mg dose to be given on the day of high-dose melphalan and three days after
Treatment: Olanzapine
- Olanzapine 5 mgExisting treatment, for comparison
Olanzapine 5 mg dose to be given on the day of high-dose melphalan and three days after
Treatment: Olanzapine
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomized, Double-Blind Study of FOND (Fosaprepitant, ONdansetron, Dexamethasone) Plus Either Olanzapine 2.5 mg Versus 5 mg for the Prevention of Chemotherapy Induced Nausea and Vomiting in Patients Receiving High-dose Melphalan Conditioning: The FONDO-LOW Study
- Plain-language title
- Two Lower Olanzapine Doses to Prevent Nausea in Myeloma PatientsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 22 November 2024